NYU Researchers Advance Blood-Based Biomarker Testing for Early Alzheimer's Detection, Identifying Disease Up to a Decade Before Symptoms
核心洞察
A research team led by Allal Boutajangout and Thomas Wisniewski at NYU Grossman School of Medicine (搜索) has demonstrated that plasma biomarkers can detect Alzheimer's-related biological changes 8–10 years before major clinical symptoms appear.
The study found strong correlations between blood biomarkers (amyloid beta (搜索), tau, and inflammation markers) and amyloid/tau deposits confirmed by PET imaging across three participant groups with varying cognitive status.
Blood-based testing could serve as a simpler, less expensive, and scalable initial screening tool, reserving PET scans and cerebrospinal fluid analysis for confirmatory cases.
A research team at New York University (NYU) Grossman School of Medicine, led by Moroccan neurologist Allal Boutajangout, PhD, and Thomas Wisniewski, MD, is making significant strides in the early detection of Alzheimer's disease (搜索) through blood-based biomarker testing. The researchers have shown that plasma biomarkers can identify biological changes associated with Alzheimer's disease eight to 10 years before major clinical symptoms become apparent, potentially reshaping how the disease is diagnosed and managed.
The approach analyzes amyloid beta (搜索) and tau proteins in blood plasma, along with other biomarkers linked to inflammation and neurological damage. In an interview with Morocco's Press Agency (MAP), Boutajangout, a research professor in the departments of neurology and neuroscience at NYU Grossman School of Medicine (搜索) and co-director of the Cognitive Neurology Center and Biomarker Platform, explained that the findings revealed close associations between blood biomarkers and amyloid and tau deposits detected through positron emission tomography (PET) imaging.
Study Design and Key Findings
The researchers examined three distinct groups: people without cognitive impairment, individuals with subjective cognitive decline (where a person notices memory or thinking problems not yet detectable through standard clinical tests), and patients with mild cognitive impairment. The study found a strong link between blood biomarkers and deposits of amyloid and tau proteins in the brain, as confirmed by PET scans. The blood biomarkers were also linked to other biological indicators associated with disease progression.
According to Boutajangout, the findings allowed researchers to identify different stages of Alzheimer's disease (搜索) with a high degree of accuracy. "The biomarkers can detect early disease pathways eight to 10 years before the main clinical signs appear," he told MAP. During this preclinical period, changes and damage in the brain may already be developing but remain difficult to detect through traditional diagnostic methods.
A Shift Toward Accessible Screening
Current diagnostic methods for Alzheimer's-related changes—including PET brain scans and cerebrospinal fluid analysis via lumbar puncture—can be expensive, invasive, and difficult to provide on a large scale. Blood-based testing, by comparison, offers a simpler, less costly, and faster alternative that could be more readily integrated into large screening programs.
Boutajangout described blood-based testing as a potential initial screening tool, with more complex and expensive tests reserved for patients whose results require further confirmation. He also noted that repeated blood tests could help doctors follow disease progression and determine which patients might benefit from treatment at different stages.
"Early detection is an important step toward preventive and precision medicine, as it could allow treatment to begin before dementia becomes clinically apparent," Boutajangout said.
Expanding the Biomarker Landscape
Speaking during the 2026 Alzheimer's Association International Conference in London, Boutajangout outlined the next phase of the research. The team plans to broaden its biomarker panels beyond amyloid and tau by examining GFAP, neurofilament light, neuroinflammation, and blood-brain barrier dysfunction. Researchers are also studying relationships between plasma biomarkers and cognitive assessments such as the Montreal Cognitive Assessment (MoCA) to better distinguish between subjective cognitive decline and mild cognitive impairment.
Thomas Wisniewski, MD, director of the NYU Langone Alzheimer's Disease (搜索) Research Center, emphasized that many patients develop several neurological pathologies simultaneously. The goal, he said, is to identify the specific combination of pathologies affecting each patient. Such biomarker profiles could eventually allow doctors to move away from a single-disease approach and select treatments according to each patient's biological disease pattern.
Boutajangout added that his team is also working to identify new proteins that could serve as biomarkers for Alzheimer's and vascular disease, opening another path toward earlier and more precise diagnosis.
Beyond Alzheimer's Disease (搜索)
The research team's work extends beyond Alzheimer's. According to Boutajangout, the group is also investigating biomarkers for other neurological and neurodegenerative conditions, including Parkinson's disease (搜索), frontotemporal dementia (搜索), traumatic brain injuries, strokes, autism, and amyotrophic lateral sclerosis (搜索) (ALS).
The research, Boutajangout told MAP, could support a broader shift toward preventive and precision medicine by giving doctors more information before cognitive decline reaches an advanced stage. Incorporating blood-based biomarker tests into screening programs could help identify people at higher risk at an earlier stage, help doctors determine whether approved treatments may be appropriate at different stages of the disease, and rule out other potentially treatable causes of cognitive problems.